OncoMatch/Clinical Trials/NCT06208371
Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
Is NCT06208371 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Palliative Chemotherapy for colorectal neoplasms malignant.
Treatment: Palliative Chemotherapy — The goal of this clinical trial is to investigate the effectiveness of localized interventions in improving the 5-year survival rate for colorectal cancer patients with ≥10 liver metastases. We aim to answer the following question: Can localized interventions, including surgery and/or ablation and/or stereotactic body radiotherapy (SBRT), enhance the 5-year survival rate compared to palliative chemotherapy alone in patients with ≥10 colorectal liver metastases (CRLM)? Participants in this study, who have achieved disease control through chemotherapy, will undergo either localized interventions (surgery and/or ablation and/or SBRT) or receive palliative chemotherapy alone. Researchers will compare the survival outcomes between these groups to determine the potential benefits of localized interventions for patients with ≥10 CRLM.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic chemotherapy
Disease control (PR or SD) achieved after a minimum of 8 cycles of systemic chemotherapy
Lab requirements
Blood counts
normal hematological function at baseline
Kidney function
normal renal function at baseline
Liver function
Child-Pugh grade A liver function; normal hepatic function at baseline
Normal hematological, hepatic, and renal functions at baseline. Child-Pugh grade A liver function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06208371 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic chemotherapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages